Completed PHASE1 INTERVENTIONAL 2-arm NCT03397641

A Phase 1 Study of HBI-3000

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Serial Cohort Dose-Escalation Study of Intravenously Administered HBI-3000

Sponsor: HUYABIO International, LLC.

Conditions Atrial Fibrillation

Interventions HBI-3000 Placebo

Updated 7 times since 2018 Last updated: Aug 28, 2018 Started: Oct 17, 2017 Primary completion: Jul 10, 2018 Completion: Jul 10, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Atrial Fibrillation and is currently completed. HUYABIO International, LLC. leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Mar 2022 [monthly]

Completed PHASE1
Sep 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 2 earlier versions

Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE1
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Oct 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

HUYABIO International, LLC.
Quotient Clinical

Data source: HUYABIO International, LLC.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nottingham, United Kingdom